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Abstract
Background: There is paucity data on the association of vitamin D deficiency (VDD) and active tuberculosis (TB) in
southern Africa where the human immunodeficiency virus (HIV) is co-endemic. We examined the association of
serum vitamin D concentrations with active pulmonary tuberculosis (PTB) in HIV-infected (n = 284) and uninfected
(n = 267) Black Zimbabweans, in Harare, Zimbabwe.
Methods: We conducted a cross-sectional study of 551 participants comprising 145 HIV+/PTB +, 139 HIV+/PTB−, 134
HIV−/PTB+ and 133 HIV−/PTB−. PTB status was confirmed using sputum by culture, or smear microscopy, or
GeneXpert MTB/RIF. Serum 25-hydroxyvitamin D (25(OH)D) concentrations were measured using a competitive
chemiluminescent immunoassay prior to commencement of anti-TB treatment.
Results: In all four groups, the median vitamin D concentrations were above the 20 ng/ml cut off for VDD.
However, the median vitamin D concentrations in all the four groups were below the cut off for vitamin D
sufficiency ≥30 ng/ml. The median vitamin D concentrations were significantly higher in PTB+ cases; 24.2 ng/ml
(IQR: 18.8–32.0) compared to PTB− controls 20.9 ng/ml (IQR: 17.1–26.9), p < 0.0001 regardless of HIV status. The HIV
+/PTB+ group had the highest median vitamin D concentration (25.3 (IQR: 18.0–33.7 ng/ml) whilst the HIV+/PTB−
group had the lowest; 20.4 ng/ml (IQR: 14.6–26.9), p = 0.0003. Vitamin D concentration <30 ng/ml was associated
with 43% lower odds of being PTB+ OR 0.57 (95% CI 0.35–0.89).
Conclusions: Our results are not in agreement with the generally accepted hypothesis that VDD is associated with
active PTB. To the contrary our results showed an association of higher vitamin D concentrations with active TB
irrespective of HIV status. Although findings from the available pool of case control studies remain inconsistent, the
results from the current study provide further rationale for larger-scale, prospectively designed studies to evaluate
whether sufficient vitamin D concentrations do indeed precede the development of active PTB in our setting.
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Background
Zimbabwe, a country ranked 17th out of 22 high burden
countries that together contribute 80% of the global tu-
berculosis (TB) burden, had a TB prevalence of 409/100
000 in 2013 [1]. The resurgence of the TB epidemic in
Zimbabwe is fuelled by HIV with ~80% co infection
rates [1].
Susceptibility to TB is associated with host immune
response which in turn may be influenced by environ-
mental and genetic factors or interactions between
the two [2, 3]. Vitamin D, an immunomodulatory ef-
fector via the vitamin D receptor, has been reported
to be critical in inducing antimycobacterial activity by
inhibiting the growth of Mycobacterium tuberculosis
(MTB) and up-regulating innate host responses [4–6].
Evidence of this was derived from in vitro studies
which demonstrated that vitamin D metabolites regu-
late the expression of cathelicidin (LL-37), an en-
dogenous antimycobacterial peptide in cultured
macrophages [7–10].
There is paucity of data on association of serum
vitamin D concentrations with TB in southern Africa
where HIV is co-endemic. We thus conducted a
cross-sectional study to measure the concentrations
of serum vitamin D and to examine their association
with active pulmonary TB (PTB) in HIV-infected and
uninfected Black Zimbabweans in Harare, Zimbabwe.
Methods
Study setting and design
Harare is located at latitude 17°55′S and longitude 31°7′E
and at an altitude of 1480 m. The study participants were
all dark skinned and unveiled, with faces and arms regu-
larly exposed to the sun.
We used stratified sampling to enrol consecutive con-
senting participants into four participant groups: HIV/TB
co-infected (HIV+/PTB+), HIV infected/PTB negative
(HIV+/PTB−), HIV uninfected/PTB positive (HIV−/PTB+)
and HIV/TB uninfected (HIV−/PTB−). HIV infected
participants were under routine care as specified by pre-
vailing national guidelines whereas PTB+ participants were
TB treatment naïve prior to measurement of serum vita-
min D concentrations.
Study participants
HIV− participants aged >18 years were recruited from
City of Harare Clinics. HIV−/PTB − participants were
healthcare workers and attendees at the institutional vol-
untary HIV testing and counseling centres with docu-
mented HIV and PTB negative status (Fig. 1). Similarly,
HIV−/PTB+ enrolled at the same centres had docu-
mented HIV and PTB status. PTB infection was con-
firmed on sputum by culture, smear microscopy or by
Xpert MTB/RIF ® (Cepheid Sunnyvale, United States).
At enrolment, sociodemographic characteristics and
clinical variables were assessed and recorded by comple-
tion of a questionnaire for all consenting participants.
Thereafter, 5mls venous blood was collected by
venipuncture from which serum was harvested by cen-
trifugation at 3000 rpm for 5 min and stored at −80 °C
until subsequent measurements of vitamin D
concentrations.
Stored serum specimens for the HIV+/PTB+ and HIV
+/PTB− groups were obtained from participants who
were enrolled in a randomised controlled trial (RCT) en-
titled ‘A randomized controlled trial to evaluate the im-
pact of using a point-of-care urine lipoarabinomannan
(LAM) strip test for TB diagnosis amongst hospitalized
HIV-infected patients in resource-poor settings (RCT
LAM)’. The RCT LAM was enrolling patients at the
same period as recruitment was taking place from the
city of Harare clinics, the institutional voluntary HIV
testing and counseling centres in Harare. Details of the
RCT are described elsewhere [11, 12]. Appropriate
demographic and laboratory data for these two groups
of participants were abstracted from the RCT LAM
database. All such data and specimens were anonymized
before access was allowed to the current investigators.
Fig. 1 Participants Enrolment Chart. HIV = Human immunodeficiency virus; HIV+ = HIV positive; HIV− = HIV negative; PTB = Pulmonary tuberculosis;
PTB+ = PTB positive; PTB− = PTB negative
Musarurwa et al. BMC Infectious Diseases  (2017) 17:142 Page 2 of 7
Case definition
PTB cases either HIV-infected or –uninfected, were spu-
tum smear microscopy or culture (using mycobacterial
growth indicator tube) or GeneXpert MTB/RIF positive.
Control definition
Controls were PTB culture negative and either HIV-
infected or uninfected.
Bacteriological testing
At enrolment, at least three sputum specimens were col-
lected from each participant for same day testing (MTB/
RIF, or microscopy). One sputum specimen was submit-
ted for culture.
Sputum smear microscopy using a fluorescence micro-
scope was done with auramine stain for screening and
confirmation of auramine positive smear was with Ziehl-
Neelsen (Z-N) stain.
The Xpert MBT/RIF assay was performed as previ-
ously described [13]. Briefly, the sample reagent was
added in a volume twice that of the untreated sputum
and incubated for 15 min. Two millimetres of the proc-
essed sputum was then transferred to the MTB/RIF
assay catridge and then inserted into the Gene Xpert
instrument.
The Mycobacteria Growth Indicator Tube (MGIT
BD Microbiology Systems, Cockeysville, MD, USA)
culture was performed on sputum decontaminated
using 4% NaOH. Suspected positive cultures were
confirmed using Z-N staining. MPT64 antigen detec-
tion was used for speciation of MGIT positive cul-
tures and by growth at different temperatures if
antigen detection was negative [14].
Vitamin D assays
Serum 25(OH)D was measured as a marker of vita-
min D status using a fully automated competitive
chemiluminescent immunoassay analyser (Maglumi
2000 Snibe Co. Ltd Shenzhen, 518057 China). The
assay was carried out in accordance with the manu-
facturer’s instructions. Serum specimens were thawed
only once for the analysis cycle. Between-run preci-
sion coefficients of variation for the assay ranged
from 6.04 to 6.25% and within run precision coeffi-
cients of variation ranged from 3.01 to 3.45%.
Serum 25(OH)D concentrations are generally accepted
as being reflective of the overall vitamin D status be-
cause of a longer half-life of approximately 15 days com-
pared to 15 h for the active form [15, 16]. Thus in this
write up, serum vitamin D concentration is used syn-
onymously with serum 25(OH)D concentration. Vitamin
D deficiency (VDD) was defined as serum 25(OH)D
concentration <20 ng/mL, vitamin D insufficiency as
serum 25(OH)D concentration ≥20–29 ng/mL, and
sufficient vitamin D status as serum 25(OH)D ≥30 ng/
ml [17, 18]. Vitamin D concentrations below 10 ng/ml
were classified as severely vitamin D deficient [19].
Ethics statement
The study protocol was approved by the Medical Re-
search Council of Zimbabwe (MRCZ/A/1906). All the
participants enrolled from the Harare City Clinics gave
their written informed consent to participate in the
study. All the participants from the RCT LAM con-
sented to use of their leftover archived specimens and
data in future TB related studies.
Statistical analyses
All statistical analyses were conducted using the STATA
statistical software package (version 13.0; Stata Corpor-
ation, College Station, Texas, USA) and GraphPad Prism
(version 5; GraphPad Prism Inc, San Diego, CA, USA).
Data were summarised by count and proportion (%) and
median and interquartile range (IQR) for non-normally
distributed variables or means ± standard deviations for
normally distributed data. Chi-square test was used to
test for differences in proportions. Differences between
groups of continuous normally distributed data were
tested using independent samples t-test and ANOVA
whilst the non-parametric Mann-Whitney or Kruskal
Wallis tests were used respectively for non-normal data.
Dunn’s test for multiple cross group rank sum compari-
sons was used to compare median vitamin D levels by
HIV/PTB status. For all statistical comparisons α was set
at 0.05. Co-variates of VDD were determined using lo-
gistic regression as was the effect of vitamin D status on
PTB status. Logistic regression was also used to deter-
mine the association between PTB and vitamin D defi-
ciency, insufficiency, optimal and severe vitamin D
deficiency. Odds ratios and their 95% confidence inter-
vals were reported for all such cases.
Results
Study population
The clinico-demographic data of the 551 study partici-
pants stratified into four groups HIV+/PTB+ (n =
145), HIV+/PTB− (n = 139), HIV−/PTB+ (n = 134) and
HIV−/PTB− (n = 133) are presented in Table 1.
The mean age of the study participants was 38.5 years
(SD12.3). Participants in the HIV−/PTB− group were sta-
tistically significantly younger than those in the HIV+/TB−
group; p = 0.002 and the HIV−/TB+ group p = 0.016
(Table 1). The proportion of males in the HIV−/TB+ (64%)
was significantly higher that of the HIV−/TB− group
(42%), p = 0.0003.
The vitamin D concentrations and status of the four
study groups are shown in Table 2.
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The overall median serum vitamin D concentration
was 22.5 ng/ml (IQR 17.7–29.3) (Table 2). Median
serum vitamin D concentrations were statistically signifi-
cantly different by HIV/PTB infection status; p = 0.0001.
The HIV+/PTB+ group had the highest median serum
vitamin D concentration 25.3 ng/ml (IQR 18.0–33.7)
whilst the HIV+/PTB− group the lowest 20.4 (IQR14.6–
26.9) ng/ml. The median serum vitamin D concentration
was statistically significantly higher for the HIV+/PTB+
group versus the HIV+/PTB− group (p < 0.0001) and the
HIV−/PTB− group (p = 0.008). The median serum vita-
min D concentration was also statistically significant
higher for the HIV−/PTB+ group versus the HIV−/PTB−
(p = 0.02) and the HIV+/PTB− group (p = <0.001). How-
ever there were no statistically significant differences in
median vitamin D concentrations between the HIV
+/PTB+ and HIV−/PTB+ groups p = 0.41 and between
the HIV+PTB− and HIV−/PTB− groups p = 0.06. None of
the four study groups had median vitamin D concentra-
tions above the optimum cut off point of 30 ng/ml
(Fig. 2).
The proportions of individuals in each of the vitamin
D status strata were significantly different across the 4
HIV/PTB participant groups (p < 0.001). (Table 2) The
HIV+/PTB− group had the highest proportion (48%) of
vitamin D deficient participants whilst the HIV−/PTB+
group had the lowest proportion (28%); p = 0.0008. The
HIV+/PTB+ group had the highest proportion (35%) of
individuals with sufficient vitamin D concentration
(≥30 ng/ml) whilst the HIV−/PTB− had the lowest pro-
portion (12%); p < 0.0001.
Correlates of serum vitamin D levels
The association between serum vitamin D status was
further analysed by comparing the median serum
vitamin D concentrations by age, gender, HIV and PTB
status (Table 3). Univariate logistic regression was con-
ducted to ascertain determinants of serum vitamin D sta-
tus. All univariate logistic regression factors with a p-value
that was less than 0.25 were included in the multiple logis-
tic regression model.
Disregarding the HIV status, PTB+ participants had
statistically significantly higher median serum vitamin D
concentration compared to PTB− participants (p <
0.0001). Median serum vitamin D concentrations were
also statistically significantly higher in females compared
to males (p = 0.017) but did not differ significantly by
HIV status or age >50 years. Gender was not a signifi-
cant correlate of vitamin D status in both univariate and
multivariate logistic analysis but age > 50 years in multi-
variate analysis was a predictor of vitamin D deficiency
with adjusted OR 1.05 (95%CI 1.01–1.1). Participants
with vitamin D concentrations <30 ng/ml were 43% less
likely to be PTB+; OR 0.57 (95% CI 0.35–0.89) and 62%
less likely to be HIV+ compared to those with sufficient
vitamin D concentrations. VDD OR 0.75 (95%CI 0.51–
1.10) and severe VDD OR 0.26 (95%CI 0.03–2.29) were
not associated with PTB positivity.
Discussion
Our study has some intriguing findings. Firstly, in our
study population the prevalence of vitamin D deficiency
was 37%. Secondly, the median serum vitamin D con-
centration in all the four groups was above the cut off
level defining VDD (<20 ng/ml), ironically with highest
medians being in the PTB+ groups regardless of HIV sta-
tus compared to the PTB− groups. Thirdly, and paradox-
ically, the PTB+ groups irrespective of HIV status had
the lowest proportions of participants with serum VDD
when compared to the PTB− groups. Fourthly, and












Age in years; mean(SD) 38.5 (12.3) 38.6(9.0) 40.5(12.6) 39.7(16.5) 35.1(8.9) 0.0017
Males n (%) 272 (51) 63(48) 70(50) 84 (64) 55 (42) *
*Significant difference between HIV+/PTB− and HIV−/PTB+ p = 0.02 and significant difference HIV−/PTB+ and HIV−/PTB−











Vitamin D ng/ml median (IQR) 22.5 (17.7–29.3) 25.3 (18.0–33.7) 20.4 (14.6–26.9) 24.0 (19.5–29.6) 21.6 (18.3–26.5)
Vitamin D status
Vitamin D deficient (n%) (<20 ng/ml) 205(37.2) 49(33.8) 67(48.2) 38(28.4) 51(38.4)
Severe vitamin D deficiency (n%) (<10 ng/ml) 6(1.1)a 0 5(3.6)a 1(0.8)a 0
Vitamin D insufficient (n%) (≥20 < 30 ng/ml) 218(39.6) 46(31.7) 42(30.2) 64(47.9) 66(49.6)
Vitamin D sufficient (n%) (≥30 ng/ml) 128(23.2) 50(34.5) 30(21.6) 32(23.9) 16(12.0)
aSevere vitamin D deficient participants also included in vitamin D deficient participant frequency
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conversely, the PTB+ groups had the highest proportions
of participants with sufficient (≥30 ng/ml) vitamin D con-
centrations compared to the PTB− controls, implying that
active PTB is associated with relatively, higher concentra-
tions of vitamin D. In support of this is the observation
that the double negative control group, (HIV−/TB−) had
the highest proportion of participants with insufficient
serum vitamin D concentrations. Fifthly and similarly,
this group had the lowest proportion of participants
with sufficient vitamin D concentrations. Indeed in a
multivariate analysis insufficient concentrations of
vitamin D were associated with a lower risk of being
PTB+. Sixthly, age >50 years was a predictor of vita-
min D deficiency.
VDD has been associated with increased risk of sev-
eral infectious and metabolic diseases [3, 20, 21]. In
vitro studies further indicate that physiological con-
centrations of 1,25 dihyroxycholecalciferol (1,25D3)
inhibit both HIV and M. tuberculosis replication in
human macrophages via an autophagy and cathelici-
din dependent mechanism [10]. The in-vivo associ-
ation between vitamin D status and tuberculosis
however remains contentious [16, 22–24].
To our knowledge, only three other studies in sub
Saharan Africa have examined the association of vitamin
D status with TB in a HIV endemic setting [16, 22, 25].
Our observations of higher median vitamin D concen-
trations, lower proportions of participants with vitamin
D deficiency and insufficiency in the PTB+/HIV+ groups
regardless of HIV status are similar to those reported in
a cross-sectional study conducted in Tanzania [25]. In
sharp contrast to our results, the observational study in
Cape Town, South Africa, with four groups of study par-
ticipants similar to our study (although their study dis-
tinguished latent from active TB), reported a high
prevalence (62.7%) of VDD (<20 ng/ml) in all the four
groups [22]. Active TB was associated with VDD in
both HIV-infected and uninfected participants with
the association being stronger in the former group.
Optimal/sufficient (>30 ng/ml) serum vitamin D con-
centrations were associated with active TB in HIV-
infected but not in the HIV-uninfected participants.
The study also reported a reciprocal seasonal vari-
ation in vitamin D status and tuberculosis notifica-
tions. We did not investigate this aspect in Zimbabwe
and we do not know if the seasonal variation may
partially explain the differences in the results from
our study. A prospective observational study with
similar study participants groups to ours (but a
smaller cohort), conducted in Uganda, reported low
prevalence of VDD with more than 50% of the partic-
ipants having optimal vitamin D concentrations in all
the four groups [16]. There were no significant differ-
ences in vitamin D status or the median vitamin D
concentrations in the four groups. The observed dif-
ferences between the two studies could be explained
by the proximity of Uganda to the equator and the
likely differences in the solar zenith angle that would
enable an individual close to the equator to synthesize
vitamin D more efficiently [26].
Fig. 2 Serum vitamin D concentrations in HIV+/PTB+ (n = 145), HIV
+/PTB− (n = 139), HIV−/TB+ (n = 134), and HIV−/PTB− (n =133). Serum
vitamin D: 25-hydroxyvitamin D; TB: Pulmonary Tuberculosis; HIV =
human immunodeficiency virus; +: Positive; −: Negative. The solid
horizontal lines ( ) indicate the median vitamin D level for each.
The broken horizontal lines (……) demarcate the cutoff points for
each vitamin D status category
Table 3 Co-variates of serum vitamin D status




Gender n = 533
1. Male n = 272 21.98 (16.4–28.5) 0.017 Referent
2. Female 22.83 (18.5–29.9) 0.8 (0.5–1.2)
Age n = 550
1. ≤50 years n = 452 22.63 (17.7–29.4) 0.409 Referent
2. >50 years 22.05 (17.6–28.8) 0.8 (0.5–1.3)
TB status n = 550
1. PTB positive n = 279 24.21 (18.8–32.0) <0.001 0.57 (0.35–0.89a
2. PTB negative 20.91 (17.1–26.9)
HIV status n = 550
Infected n = 283 22.14 (16.4–31.5) 0.394 0.38 (0.24–0.60)a
1.86 (1.26–2.75)b
Uninfected 22.63 (18.9–28.4)
aThe odds ratio referent was hypovitaminosis D <30 ng/ml compared to
optimal vitamin D concentration >30 ng/ml
bReferent was serum vitamin D <20 ng/ml
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Although our findings are discordant with the gener-
ally accepted hypothesis that VDD is associated with
PTB [22, 23], they are biologically plausible. PTB infec-
tion infamously known as ‘the consumption’ [27] in the
past, could lead to higher vitamin D levels by two mech-
anisms. Adipose tissue is a reservoir of vitamin D [28]
and wasting associated with PTB could result in in-
creased release of sequestered vitamin D into circulation.
Higher vitamin levels reported by others, in participants
with body mass index (BMI) ≤ 18.5 compared to those of
higher BMI lend further support to our speculation
[22, 25]. On the other hand, MTB induces expression
of 1-α-hydroxylase (CYP27B1) in macrophages thus
mediating local conversion of 25(OH)D to 1,25D3.
This induction enhances the ability of macrophages to
restrict mycobacterial growth [6, 10]. Heightened im-
mune activation in HIV+/PTB+ participants might
therefore lead to increased consumption of 25(OH) D
and its further mobilisation from adipose tissue into
circulation.
Several other studies to examine vitamin D status
and association with PTB have been conducted glo-
bally albeit with conflicting results. In general, studies
performed in African [19, 22, 29, 30] and Caucasian
populations [31] have reported lower vitamin D con-
centrations in TB patients than in controls while the
results from Asia are variable. There were no signifi-
cant differences in median vitamin D concentrations
between TB cases and controls in Indonesia [32]
China [33], South Korea [34] and Afghanistan [35]. In
contrast, in a recent study conducted in Vietnam,
vitamin D insufficiency was more prevalent in males
with TB than in controls [36].
The geographical variation of vitamin D status and as-
sociation with TB may be attributable to differences in
cultural behaviours, exposure to sunshine, dietary intake
of vitamin D, and genetic factors. A study of Asians in
London reported that genetic polymorphisms in the
vitamin D receptor gene can result in differing suscepti-
bility to VDD [23].
The conflicting results on the association of vitamin D
deficiency with an increased risk of PTB may also be at-
tributable to the differing criteria for VDD. In some stud-
ies, a concentration of 25-(OH)D3 < 20 ng/ml was used as
a cut off [19, 22, 23], while other studies used a concentra-
tion of 25-(OH)D3 of <25 nmol/L [34, 36]. Some studies
used other criteria such as 25–50 nmol/L [16]. The cri-
teria for other commonly used terminologies such as
vitamin D insufficiency, severe insufficiency and suffi-
cient and their association with TB also vary across
the studies [16, 19, 22, 23, 35] We selected the vita-
min D deficiency, insufficiency and sufficiency thresh-
olds as widely recommended in other studies [17, 18].
Mao et al. raise a point of caution on the possibility
that the cut off points as suggested by the Institute of
Medicine, which are based on skeletal health for a
predominantly Caucasian population, may not be ideal
for other races in other settings [37]. It might there-
fore be prudent to establish local reference intervals
for different settings and racial groups.
Limitations
A major limitation of the current analysis is the cross-
sectional design which precludes causal inferences to be
made on the observed associations due to lack of tempor-
ality and the possibility of reverse causality. The
unmatched nature of the comparison groups in this cross-
sectional design probably also impedes drawing of stron-
ger conclusions. Other limitations include lack of data on
sunshine exposure and dietary habits. Despite these, the
study had a major advantage of a fairly large sample size
and also included HIV+ and HIV− comparison groups un-
like some similarly designed studies that were underpow-
ered or did not include PTB− comparison groups.
Conclusions
In our study vitamin D concentration <30/ng/ml, were
associated with lower odds of being PTB+. Paradoxically,
the PTB+ groups regardless of HIV status not only had
the highest median serum vitamin D concentrations but
also the highest proportion of participants with sufficient
vitamin D concentration (≥30 ng/ml) implying that
higher median and optimal vitamin D concentrations
are associated with active PTB. We recommend pro-
spective studies to evaluate whether sufficient vitamin D
concentrations precede the development of active PTB.
Abbreviations
25(OH)D: 25-hydroxyvitamin D; ANOVA: Analysis of variance; BMI: Body mass
index; HIV: Human immunodeficiency virus; IQR: Interquartile range;
LAM: Lipoarabinomannan; MRCZ: Medical research council of Zimbabwe;
MTB: Mycobacterium tuberculosis; OR: Odds ratio; PTB: Pulmonary tuberculosis;
RCT: Randomised controlled trial; SD: Standard deviation; TB: Tuberculosis;





The authors gratefully acknowledge funding from the European and
Developing Countries Trials Partnership (IP.0932040009), Southern Africa
Consortium for Research Excellence and grant number 2U2RTW007367 from
the Fogarty International Centre, National Institutes of Health, USA through
the International Clinical, Operations, and Health Services Research Training
Award for AIDS and TB. The funders played no role in the design of the
study and collection, analysis, and interpretation of data and in writing the
manuscript.
Availability of data and materials
The datasets used during and/or analysed during the current study available
from the corresponding author on reasonable request.
Musarurwa et al. BMC Infectious Diseases  (2017) 17:142 Page 6 of 7
Authors’ contributions
CM, LSZ, WBM and MWM conceived the study and its design. CM, MMC and
DZD participated in the collection of clinical material and study participant
recruitment. CM, DZD and KM conducted laboratory tests. KMD and CM
performed data analysis. CM wrote the first draft with input from LSZ, WBM,
MWM, DZD, KM, KMD and MMC. All authors reviewed and approved the
final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not Applicable.
Ethics approval and consent to participate
The study protocol was approved by the Medical Research Council of
Zimbabwe (MRCZ/A/1906). All participants gave written informed consent
whilst all participants with archived specimens consented to future use in TB
related studies.
Author details
1Department of Chemical Pathology, University of Zimbabwe, College of
Health Sciences, P.O. Box A178, Avondale, Harare, Zimbabwe. 2Department of
Immunology, University of Zimbabwe, College of Health Sciences, P.O. Box
A178, Avondale, Harare, Zimbabwe. 3Research Support Centre, University of
Zimbabwe, College of Health Sciences, P.O. Box A178, Avondale, Harare,
Zimbabwe. 4Department of Obstetrics and Gynaecology, University of
Zimbabwe, College of Health Sciences, P.O. Box A178, Avondale, Harare,
Zimbabwe.
Received: 20 July 2016 Accepted: 3 February 2017
References
1. WHO. Global Tuberculosis Report 2014. Geneva: World Health Organization;
2014. http://www.who.int/tb/publications/global_report/en/. Accessed 21
Dec 2014.
2. Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ. Reactivation of
tuberculosis and vitamin D deficiency: the contribution of diet and
exposure to sunlight. Thorax. 2007;62:1003–7.
3. Leandro ACCS, Rocha MA, Cardoso CSA, Bonecini-Almeida MG. Genetic
polymorphisms in vitamin D receptor, vitamin D-binding protein, Toll-like
receptor 2, nitric oxide synthase 2, and interferon- -γ genes and its
association with susceptibility to tuberculosis. Braz J Med Biol Res. 2009;42:
312–22.
4. Nava-Aguilera E, Andersson N, Harris E, Mitchell S, Hamel C, Shea B, et al. Risk
factors associated with recent transmission of tuberculosis: systematic review
and meta-analysis [Review article]. Int J Tuberc Lung Dis. 2009;13:17–26.
5. Wu G, Zhao M, Gu X, Yao Y, Liu H, Song Y. The effect of P2X7 receptor 1513
polymorphism on susceptibility to tuberculosis: A meta-analysis. Infect
Genet Evol. 2014;24:82–91.
6. Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW,
Skolimowska K, et al. IFN-γ-and TNF-independent vitamin D-inducible
human suppression of mycobacteria: the role of cathelicidin LL-37.
J Immunol. 2007;178:7190–8.
7. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin D-mediated
human antimicrobial activity against Mycobacterium tuberculosis is
dependent on the induction of cathelicidin. J Immunol. 2007;179:2060–3.
8. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial
peptide (CAMP) gene is a direct target of the vitamin D receptor and is
strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB
J. 2005;19:1067–77.
9. Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins: microbicidal
activity, mechanisms of action, and roles in innate immunity. Microb Infect.
2002;4:361–72.
10. Campbell GR, Spector SA. Vitamin D inhibits human immunodeficiency virus
type 1 and Mycobacterium tuberculosis infection in macrophages through
the induction of autophagy. PLoS Pathog. 2012;8(5):e1002689.
11. Zijenah LS, Kadzirange G, Bandason T, Chipiti MM, Gwambiwa B, Makoga F,
et al. Comparative performance characteristics of the urine
lipoarabinomannan strip test and sputum smear microscopy in hospitalized
HIV-infected patients with suspected tuberculosis in Harare, Zimbabwe.
BMC Infect Dis. 2016;16:1.
12. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on
mortality of point-of-care, urine-based lipoarabinomannan testing to guide
tuberculosis treatment initiation in HIV-positive hospital inpatients: a
pragmatic, parallel-group, multicountry, open-label, randomised controlled
trial. Lancet. 2016;387:1187–97.
13. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of
tuberculosis and rifampin resistance. N Engl J Med. 2010;363:1005–15.
14. SD Standard Diagnostics. Available: http://www.standardia.com/en/home/
product/rapid/infectious-disease/TB_Ag_MPT64.htm. Accessed 27 Jan 2015.
15. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:
582S–6.
16. Conesa-Botella A, Goovaerts O, Massinga-Loembe M, Worodria W,
Mazakpwe D, Luzinda K, et al. Low prevalence of vitamin D deficiency in
Ugandan HIV-infected patients with and without tuberculosis. Int J Tuberc
Lung Dis. 2012;16:1517–21.
17. Holick MF, Vitamin D. Deficiency. N Engl J Med. 2007;357:266–81.
18. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R.
Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–6.
19. Wejse C, Olesen R, Rabna P, Kaestel P, Gustafson P, Aaby P, et al. Serum 25-
hydroxyvitamin D in a West African population of tuberculosis patients and
unmatched healthy controls. Am J Clin Nutr. 2007;86:1376–83.
20. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the
risk of mortality in the general population. Arch Intern Med. 2008;168:1629–37.
21. Zittermann A, Schleithoff SS, Frisch S, Götting C, Kuhn J, Koertke H, et al.
Circulating calcitriol concentrations and total mortality. Clin Chem. 2009;55:
1163–70.
22. Martineau AR, Nhamoyebonde S, Oni T, Rangaka MX, Marais S, Bangani N, et al.
Reciprocal seasonal variation in vitamin D status and tuberculosis notifications
in Cape Town, South Africa. Proc Natl Acad Sci. 2011;108:19013–7.
23. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al.
Influence of vitamin D deficiency and vitamin D receptor polymorphisms
on tuberculosis among Gujarati Asians in west London: a case–control
study. Lancet. 2000;355:618–21.
24. Nielsen NO, Skifte T, Andersson M, Wohlfahrt J, Søborg B, Koch A, et al. Both
high and low serum vitamin D concentrations are associated with
tuberculosis: a case control study in Greenland. Br J Nutr. 2010;104:1487–91.
25. Friis H, Range N, Changalucha J, PrayGod G, Jeremiah K, Faurholt-Jepsen D,
et al. Vitamin D status among pulmonary TB patients and non-TB controls:
A cross-sectional study from Mwanza, Tanzania. PLoS One. 2013;8:e81142.
26. Engelsen O. The relationship between ultraviolet radiation exposure and
vitamin D status. Nutrients. 2010;2:482–95.
27. Herzog H. History of tuberculosis. Respiration. 1998;65:5–15.
28. Mutt SJ, Hyppönen E, Saarnio J, Järvelin MR, Herzig KH. Vitamin D and
adipose tissue—more than storage. Front Physiol. 2014;5(228):1–9.
29. Davies PD, Church HA, Brown RC, Woodhead JS. Raised serum calcium in
tuberculosis patients in Africa. Eur J Respir Dis. 1987;71:341–4.
30. Mastala Y, Nyangulu P, Banda RV, Mhemedi B, White SA, Allain TJ. Vitamin D
deficiency in medical patients at a central hospital in Malawi: a comparison
with TB patients from a previous study. PLoS One. 2013;8:e59017.
31. Davies PDO, Brown RC, Woodhead JS. Serum concentrations of vitamin D
metabolites in untreated tuberculosis. Thorax. 1985;40:187–90.
32. Grange JM, Davies PDO, Brown RC, Woodhead JS, Kardjito T. A study of
vitamin D levels in Indonesian patients with untreated pulmonary
tuberculosis. Tubercle. 1985;66:187–91.
33. Chan TY, Poon P, Pang J, Swaminathan R, Chan CH, Nisar M, et al. A study
of calcium and vitamin D metabolism in Chinese patients with pulmonary
tuberculosis. J Trop Med Hyg. 1994;97:26–30.
34. Hong JY, Kim SY, Chung KS, Kim EY, Jung JY, Park MS, et al. Association
between vitamin D deficiency and tuberculosis in a Korean population. Int J
Tuberc Lung Dis. 2014;18:73–8.
35. Sarin P, Duffy J, Mughal Z, Hedayat E, Manaseki-Holland S. Vitamin D and
tuberculosis: review and association in three rural provinces of Afghanistan.
Int J Tuberc Lung Dis. 2016;20:383–8.
36. Ho-Pham LT, Nguyen ND, Nguyen TT, Nguyen DH, Bui PK, Nguyen VN, et al.
Association between vitamin D insufficiency and tuberculosis in a
Vietnamese population. BMC Infect Dis. 2010;10:306.
37. Mao X, Zheng H, Liu Z, Wu Y, Na R, Wang C, et al. Analysis of 25 (OH) D
serum concentrations of hospitalized elderly patients in the shanghai area.
PLoS One. 2014;9:e90729.
Musarurwa et al. BMC Infectious Diseases  (2017) 17:142 Page 7 of 7
